Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT01859234
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
Overview
The purpose of this study is to see whether 89Zr-bevacizumab PET scanning is feasible in relapsing multiple myeloma patients.
Phase
N/A
Contacts
E G de Waal, MD (CONTACT)
e.g.m.de.waal@umcg.nl
+31503612354
E vellenga, PhD/MD (CONTACT)
e.vellenga@umcg.nl
+31503612354
ClinicalTrials.gov
NCT01859234Eligibility
Inclusion
- New hypercalcaemia -
- New lytic lesions or progression of old lesions
- Increase of urine paraprotein with more than 25%
- More than 5% plasma cells in bone marrow.
- New lytic lesions or progression of old lesions.
- Reappearance of paraprotein
- Increase of plasma cells in bone marrow with 10%
- Patients with relapsing multiple myeloma according to international defined guidelines:Relapse after having achieved complete remission:
- New hypercalcaeamia.Relapse after having achieved partial remission
- Increases of paraprotein with more than 25%
Exclusion
- Radiotherapy in the last 3 months.
- Severe kidney dysfunction; serum-creatinine ≥250 µM
- Pregnancy.
- Claustrophobia
- Ineligible to lay supine during the PET scan.
Share your feedback
Help us improve your experience